OPK
OPKO HEALTH, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 20 ▲ 1 insider buy $11.3K at $1.14
- Apr 22 ▲ OPKO Health announced the initiation of patient dosing in a Phase 1…
- Apr 22 FDA: OPKO Health’s ModeX Therapeutics Begins Clinical Trial of…
- Apr 30 Contract: OPKO Health Expands Nicoya Agreement to Support RAYALDEE®…
- Jun 15 FDA: Preclinical Data for OPKO Biologics' OPK8801001 in Acromeg…
- Oct 15 ▲ OPKO Health (OPK) has agreed to sell its BioReference clinical and a…
- Oct 16 ▲ Barrington Research upgrades
- Nov 4 OPKO reported Q3 2026 continuing operations revenue of $65.4M (+16%…
- Nov 4 ▲ Earnings: OPK Q3 2026 Earnings: EPS $-0.05 (+27.2% vs est)
- Nov 5 ▼ 1 insider sell $24.6K at $1.81
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider bought $11.3K at an average $1.14. 1 insider sold $24.6K. Price is 43% above their cost.
- InstitutionsBULLISH
Q3 2026: 21 added (0 new), 13 trimmed or exited.
- AnalystsBULLISH
8 of 10 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest −3.4% to 32.85M shares. 9.2 days to cover, ≈4.4% of shares.
- TrendUPTREND
1% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| UBS Group AG | TRIM | $4.7M |
| Clearstead Advisors, LLC | ADD | $1.8M |
| JPMORGAN CHASE & CO | DOUBLED | $1.3M |
| Connor, Clark & Lunn Investment Management Ltd. | ADD | $1.2M |
| BARCLAYS PLC | DOUBLED | $400.3K |
| Squarepoint Ops LLC | DOUBLED | $341.6K |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | $230.7K |
| GROUP ONE TRADING LLC | ADD | $145.1K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
10 analystsPrice is below the lowest target. Median implies +85%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 16, 2026 | Piper Sandler REITERATE | Overweight |
| Oct 16, 2026 | Barrington Research UPGRADE | Outperform |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
PAGANELLI JOHN A Director Nov 5, 2026 | SELL | $16.7K |
PAGANELLI JOHN A Director Nov 5, 2026 | SELL | $7.9K |
Rubin Steven D Executive VP-Administration Jul 24, 2026 | TAX W/H | $65.0K |
Logal Adam Sr. Vice President, CFO Jul 24, 2026 | TAX W/H | $65.0K |
PFENNIGER RICHARD C JR Director Jun 18, 2026 | AWARD | 60,000 sh |
Lachman Prem A Director Jun 18, 2026 | AWARD | 30,000 sh |
Yu Alice Lin-Tsing Director Jun 18, 2026 | AWARD | 30,000 sh |
UPPALURI SUBBARAO V Director Jun 18, 2026 | AWARD | 80,000 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
7 filings · 3 press releases · 1 bullish · 0 bearish · 1 mixed · 5 neutral- NEUTRAL 8-KNov 4, 2026
OPKO reported Q3 2026 continuing operations revenue of $65.4M (+16% YoY), above the $136.6M…
The Labcorp sale transforms OPKO into a pure-play biopharma company, removing the loss-making diagnostics segment. Watch for regulatory approval timeline and closing conditions for the $722M deal…
- NEUTRAL PRESS-RELEASENov 4, 2026
OPKO reported Q3 2026 continuing operations revenue of $65.4M (+16% YoY), above the $136.6M…
Monitor regulatory approvals and closing timeline for the Labcorp transaction, which will transform OPKO into a pure-play biopharma company. The $125M royalty financing provides near-term liquidity…
- BULLISH 8-KOct 15, 2026
OPKO Health (OPK) has agreed to sell its BioReference clinical and anatomic pathology laboratory…
Watch for HSR clearance and any regulatory challenges to the deal. The earnout structure means OPK retains upside from 4Kscore performance. Post-close, OPKO's remaining business (Excluded Business)…
- MIXED 8-KJul 27, 2026
OPKO Health reported Q2 2026 revenue of $163.5M, above the $131.2M consensus estimate, and a net…
The headline beat is misleading due to non-recurring items. Monitor the Q3 2026 earnings for organic revenue growth in diagnostics and pharmaceuticals, and track cash burn rate. The raised full-year…
All OPK filing & press-release reports (10)
- PRESS-RELEASE reportNov 4, 2026
- 8-K reportNov 4, 2026
- 8-K reportOct 15, 2026
- 8-K reportJul 27, 2026
- PRESS-RELEASE reportJul 23, 2026
- PRESS-RELEASE reportJun 15, 2026
- DEFA14A reportMay 15, 2026
- PRESS-RELEASE reportApr 30, 2026
- PRESS-RELEASE reportApr 22, 2026
- PRESS-RELEASE reportApr 21, 2026